Journal of Clinical Oncology, Vol 15, 712-722, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

NC Choi, RW Carey, W Daly, D Mathisen, J Wain, C Wright, T Lynch, M Grossbard and H Grillo
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. choi.noah@mgh.harvard.edu

PURPOSE: The main objectives of this study were (a) to ascertain the feasibility and toxicity of preoperative twice-daily radiation therapy and concurrent chemotherapy, surgery, and postoperative therapy in stage IIIA (N2) non-small-cell lung cancer (NSCLC), and (b) to evaluate tumor response, resection rate, pathologic tumor downstaging, and survival. METHODS: Eligibility included biopsy-proven N2 lesion (stage IIIA) by mediastinoscopy, Karnofsky performance score > or = 70, and weight loss less than 5% in the 3 months before diagnosis. The treatment program consisted of two courses of preoperative cisplatin, vinblastine, and fluorouracil (5-FU); 42 Gy concurrent radiation at 1.5 Gy per fraction in two fractions per day; surgery on day 57; and one more course of postoperative chemotherapy and 12 to 18 Gy of concurrent twice-daily radiation. RESULTS: Forty-two patients with stage IIIA (N2) NSCLC (27 men and 15 women, age 38 to 77 years) were enrolled onto this prospective study. Forty of 42 patients tolerated the intended dose (42 Gy) of preoperative radiation and 37 of 39 resected patients received prescribed postoperative radiation. The intended dose of chemotherapy was given in 100%, 70%, and 60% of patients for the first, second, and third courses of chemotherapy. Marked dysphagia that required intravenous hydration was noted in 14% of patients (six of 42). Myelotoxicities included grade > or = 3 granulocytopenia in 23% and thrombocytopenia in 6% of 113 chemotherapy courses. Febrile neutropenia that required hospital admission was noted in 9% of 113 chemotherapy courses. Surgical resection was performed in 93% of patients. Treatment- related mortality was noted in 7% of patients. The overall survival rates by the Kaplan-Meier method were 66%, 37%, and 37% at 2,3, and 5 years, respectively, with a median follow-up time of 48 months. Pathologic examination of the surgical specimen showed a downward shift in tumor extent from stage IIIA (N2) to stage II (N1) in 33%, to stage I (NO) in 24% (10 of 42), and to stage 0 (TONO) in 9.5%, for a total of 67%. The degree of tumor downstaging was also translated into a survival benefit: 5-year survival rates from the time of surgery were 79%, 42%, and 18% for postoperative tumor stages 0 and I, II, and III, respectively (P = .04). CONCLUSION: Concurrent chemoradiotherapy using twice-daily radiation is an effective induction regimen that resulted in 67% tumor downstaging, and an encouraging 37% 5-year survival rate. The degree of tumor downstaging may be a useful intermediate end point for survival benefit in stage IIIA (N2) NSCLC.

This article has been cited by other articles:

				R. Bordoni Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer Oncologist, September 1, 2008; 13(9): 945 - 953. [Abstract] [Full Text] [PDF]

				N. Pourel, N. Santelmo, N. Naafa, A. Serre, W. Hilgers, L. Mineur, N. Molinari, and F. Reboul Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 829 - 836. [Abstract] [Full Text] [PDF]

				C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				C. D. Wright, N. C. Choi, J. C. Wain, D. J. Mathisen, T. J. Lynch, and P. Fidias Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors Ann. Thorac. Surg., February 1, 2008; 85(2): 385 - 389. [Abstract] [Full Text] [PDF]

				C. Pottgen, W. Eberhardt, A. Grannass, S. Korfee, G. Stuben, H. Teschler, G. Stamatis, H. Wagner, B. Passlick, V. Petersen, et al. Prophylactic Cranial Irradiation in Operable Stage IIIA Non Small-Cell Lung Cancer Treated With Neoadjuvant Chemoradiotherapy: Results From a German Multicenter Randomized Trial J. Clin. Oncol., November 1, 2007; 25(31): 4987 - 4992. [Abstract] [Full Text] [PDF]

				P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742. [Abstract] [Full Text] [PDF]

				H. Yokomise, M. Gotoh, T. Okamoto, Y. Yamamoto, S. Ishikawa, T. Nakashima, D. Masuya, D. Liu, and C.-l. Huang Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non small cell lung cancer J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1179 - 1185. [Abstract] [Full Text] [PDF]

				A. Granetzny, A. Boseila, W. Wagner, G. Krukemeyer, U. Vogt, E. Hecker, O. M. Koch, and F. Klinke Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 212 - 216. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]

				S. Fujita, N. Katakami, Y. Takahashi, K. Hirokawa, A. Ikeda, C. Tabata, T. Mio, and M. Mishima Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 896 - 901. [Abstract] [Full Text] [PDF]

				D. Galetta, A. Cesario, S. Margaritora, V. Porziella, A. Piraino, R. M. D'Angelillo, M. A. Gambacorta, S. Ramella, L. Trodella, S. Valente, et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 314 - 321. [Abstract] [Full Text] [PDF]

				C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106. [Abstract] [Full Text] [PDF]

				M. M. DeCamp Jr., S. Ashiku, and R. Thurer The Role of Surgery in N2 Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5033s - 5037s. [Abstract] [Full Text] [PDF]

				M. Semik, D. Riesenbeck, A. Linder, C. Schmid, P. Hoffknecht, A. Heinecke, H. H. Scheld, M. Thomas, and for The German Lung Cancer Cooperative Group Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1205 - 1210. [Abstract] [Full Text] [PDF]

				T. J. Lynch, C. D. Wright, N. C. Choi, S. L. Aquino, and E. J. Mark Case 26-2004 - A 56-Year-Old Woman with Cough and a Lung Nodule N. Engl. J. Med., August 19, 2004; 351(8): 809 - 817. [Full Text] [PDF]

				L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging Ann. Onc., March 1, 2004; 15(3): 389 - 398. [Abstract] [Full Text] [PDF]

				F. Barlesi, C. Doddoli, B. Chetaille, J.-P. Torre, R. Giudicelli, P. Thomas, J.-P. Kleisbauer, and P. Fuentes Survival and postoperative complication in daily practice after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 558 - 562. [Abstract] [Full Text] [PDF]

				D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809. [Abstract] [Full Text] [PDF]

				M. M. DeCamp, T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, S. C. Murthy, and E. H. Blackstone Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 17 - 25. [Abstract] [Full Text] [PDF]

				H. Kimura, N. Iwai, S. Ando, K. Kakizawa, N. Yamamoto, H. Hoshino, and T. Anayama A prospective study of indications for mediastinoscopy in lung cancer with CT findings, tumor size, and tumor markers Ann. Thorac. Surg., June 1, 2003; 75(6): 1734 - 1739. [Abstract] [Full Text] [PDF]

				D. C. Betticher, S.-F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, et al. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial J. Clin. Oncol., May 1, 2003; 21(9): 1752 - 1759. [Abstract] [Full Text] [PDF]

				L. J. Wirth, J. Lucca, P. Ostler, P. Fidias, C. Lynch, P. A. Janne, R. S. Herbst, B. E. Johnson, D. J. Sugarbaker, D. J. Mathisen, et al. Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: A Phase I Study Clin. Cancer Res., May 1, 2003; 9(5): 1698 - 1704. [Abstract] [Full Text] [PDF]

				A. Granetzny, E. Striehn, U. Bosse, W. Wagner, O. Koch, U. Vogt, P. Froeschle, and F. Klinke A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer Ann. Thorac. Surg., April 1, 2003; 75(4): 1107 - 1112. [Abstract] [Full Text] [PDF]

				M. Ohta, N. Sawabata, H. Maeda, and H. Matsuda Efficacy and safety of tracheobronchoplasty after induction therapy for locally advanced lung cancer J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 96 - 100. [Abstract] [Full Text] [PDF]

				E. Cetinkaya, A. Turna, P. Yildiz, R. Dodurgali, M. A. Bedirhan, A. Gurses, and V. Yilmaz Comparison of clinical and surgical-pathologic staging of the patients with non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., December 1, 2002; 22(6): 1000 - 1005. [Abstract] [Full Text] [PDF]

				G. Stamatis, D. Djuric, W. Eberhardt, C. Pottken, G. Zaboura, S. Fechner, and T. Fujimoto Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients Eur. J. Cardiothorac. Surg., August 1, 2002; 22(2): 292 - 297. [Abstract] [Full Text] [PDF]

				C. D. Wright, M. T. Menard, J. C. Wain, D. M. Donahue, H. C. Grillo, T. J. Lynch, N. C. Choi, and D. J. Mathisen Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus Ann. Thorac. Surg., May 1, 2002; 73(5): 1541 - 1544. [Abstract] [Full Text] [PDF]

				C. Pottgen, W. Eberhardt, S. Bildat, G. Stuben, G. Stamatis, L. Hillejan, S. Sohrab, H. Teschler, S. Seeber, H. Sack, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial Ann. Onc., March 1, 2002; 13(3): 403 - 411. [Abstract] [Full Text] [PDF]

				L. Trodella, P. Granone, S. Valente, A. Turriziani, G. Macis, G. M. Corbo, S. Margaritora, A. Cesario, R. M. D'Angelillo, G. Gualano, et al. Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2002; 20(3): 804 - 810. [Abstract] [Full Text] [PDF]

				J.F. Vansteenkiste Imaging in lung cancer: positron emission tomography scan Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s. [Abstract] [Full Text] [PDF]

				K. Junker, K. Langner, F. Klinke, U. Bosse, and M. Thomas Grading of Tumor Regression in Non-small Cell Lung Cancer : Morphology and Prognosis Chest, November 1, 2001; 120(5): 1584 - 1591. [Abstract] [Full Text] [PDF]

				D. H. Grunenwald, F. Andre, C. Le Pechoux, P. Girard, C. Lamer, A. Laplanche, M. Tarayre, R. Arriagada, and T. Le Chevalier Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 796 - 802. [Abstract] [Full Text] [PDF]

				T. L. Evans and T. J. Lynch Jr. Lung Cancer Oncologist, October 1, 2001; 6(5): 407 - 414. [Abstract] [Full Text] [PDF]

				J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF]

				R. Bueno, W. G. Richards, S. J. Swanson, M. T. Jaklitsch, J. M. Lukanich, S. J. Mentzer, and D. J. Sugarbaker Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann. Thorac. Surg., December 1, 2000; 70(6): 1826 - 1831. [Abstract] [Full Text] [PDF]

				M. Sonobe, M. Nakagawa, M. Ichinose, N. Ikegami, M. Nagasawa, and T. Shindo Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 519 - 523. [Abstract] [Full Text] [PDF]

				F. Andre, D. Grunenwald, J.-P. Pignon, A. Dujon, J. L. Pujol, P. Y. Brichon, L. Brouchet, E. Quoix, V. Westeel, and T. Le Chevalier Survival of Patients With Resected N2 Non-Small-Cell Lung Cancer: Evidence for a Subclassification and Implications J. Clin. Oncol., August 16, 2000; 18(16): 2981 - 2989. [Abstract] [Full Text] [PDF]

				G. M. Strauss Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer* Chest, December 1, 1999; 116(suppl_3): 509S - 516S. [Abstract] [Full Text] [PDF]

				G. Stamatis, W. Eberhardt, G. Stuben, S. Bildat, O. Dahler, and L. Hillejan Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results Ann. Thorac. Surg., October 1, 1999; 68(4): 1144 - 1149. [Abstract] [Full Text] [PDF]

				M. Stuschke, W. Eberhardt, C. Pottgen, G. Stamatis, H. Wilke, G. Stuben, F. Stoblen, H. H. Wilhelm, H. Menker, H. Teschler, et al. Prophylactic Cranial Irradiation in Locally Advanced Non-Small-Cell Lung Cancer After Multimodality Treatment: Long-Term Follow-Up and Investigations of Late Neuropsychologic Effects J. Clin. Oncol., September 1, 1999; 17(9): 2700 - 2700. [Abstract] [Full Text] [PDF]

				K. Suzuki, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, and Y. Nishiwaki THE PROGNOSIS OF SURGICALLY RESECTED N2 NON-SMALL CELL LUNGCANCER: THE IMPORTANCE OF CLINICAL N STATUS J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 145 - 153. [Abstract] [Full Text] [PDF]

				M. Thomas, C. Rube, M. Semik, M. von Eiff, L. Freitag, H. N. Macha, W. Wagner, F. Klinke, H. H. Scheld, N. Willich, et al. Impact of Preoperative Bimodality Induction Including Twice-Daily Radiation on Tumor Regression and Survival in Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., April 1, 1999; 17(4): 1185 - 1185. [Abstract] [Full Text] [PDF]

				T. W. Rice, D. J. Adelstein, J. P. Ciezki, M. E. Becker, L. A. Rybicki, C. F. Farver, M. A. Larto, and E. H. Blackstone Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Ann. Thorac. Surg., December 1, 1998; 66(6): 1909 - 1914. [Abstract] [Full Text] [PDF]